AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01134679 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-disciplinary disease management approach
Description: Follow up with phone calls
Study NCT02012790 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: The dietary intervention provides dietary counseling, whole foods (enough for 2 meals and 2 snacks per day) including study oils
Study NCT02012790 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: The dietary intervention provides dietary counseling, whole foods (enough for 2 meals and 2 snacks per day) including study oils
Study NCT03229928 — intervention group
Intervention type: DEVICE
Intervention: MOCHA
Description: * MOCHA phone-based application~* Event tracker button that marks the beginning and end of a behavioral event. Similar to a FOB that connects to MOCHA application via bluetooth~* Wrist based sensor (applicable only to sensor wearing participants).
Study NCT05902091 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurophysiology-based intervention
Study NCT00893347 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Single session with early intervention coordinator for assessment, education about mild traumatic brain injury, and recommendations for symptom management.
Study NCT00893347 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Single session with early intervention coordinator for assessment, education about mild traumatic brain injury, and recommendations for symptom management.
Study NCT04257032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Tablet
Study NCT04257032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin + BI 1323495
Description: Tablets
Study NCT00893347 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy
Description: 6-session manualized cognitive-behavioural therapy protocol designed to prevent persistent post-concussion syndrome
Study NCT00832195 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Motion Controlling Running Shoe
Description: Running shoe with thermoplastic mid-foot shank stiffener, denser durometer foam on medial aspect of mid-sole, reinforced heel counter, wider sole-plate, and lateral foam crash-pad.
Study NCT00832195 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neutral Running Shoe
Description: Standard running shoe with single density mid-sole foam.
Study NCT02442843 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: Participants will be randomized into active or sham stimulation in the first tDCS session. Participants will then have the option to complete 9 additional session of tDCS which will be active tDCS or a combination of active and sham tDCS in a non-randomized manner over two consecutive weeks. Each session will last 1 - 2 hours.
Study NCT02442843 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Participants will be randomized into active or sham stimulation in the first tDCS session. Participants will then have the option to complete 9 additional session of tDCS which will be active tDCS or a combination of active and sham tDCS in a non-randomized manner over two consecutive weeks. Each session will last 1 - 2 hours.
Study NCT04257032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: Capsule
Study NCT04257032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate + BI 1323495
Description: Capsule and tablets
Study NCT03644823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: PDL1- inhibitor
Study NCT03644823 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 6 Gy x 3
Study NCT00737295 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CCK Injection and Ultrasound
Description: All subjects, whether they participate in this study or not, will undergo the HIDA scan as this is the accepted standard of care for diagnosing biliary dyskinesia. If a given subject agrees to participate in this study, he/she will be asked to undergo the following study procedures:~If a pregnancy test has not already been done, a urine pregnancy test will be done for women of childbearing potential.~An intravenous line (IV) will be inserted (if not already in place), and a standard dose of CCK (Kinevac®- 0.02 µg/kg) will then be injected according to the package insert. Ultrasound will be used to measure dimensions of the gallbladder (length, width and height) every minute for 35 minutes following injection of the CCK. This will be done by applying ultrasound jelly to the upper part of the abdomen and ultrasound probe will be used to obtain optimal images for three dimensional analysis of the subject's gallbladder.
Study NCT00697190 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A toric
Description: silicone hydrogel contact lens for patients with astigmatism
Study NCT00697190 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: galyfilcon A toric
Description: silicone hydrogel contact lens for patients with astigmatism
Study NCT01632943 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Symplicity renal denervation system
Description: Previous research has shown that disrupting the nerves of the kidney may successfully decrease blood pressure.~A less invasive approach to disrupting these nerves is to apply a brief high temperature near the nerves (renal denervation). This can now be done with an experimental medical device called the Symplicity renal denervation system. The System includes a catheter that is inserted into your blood vessels and an RF-generator.
Study NCT04444518 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VAX-MOM Intervention
Description: The multi-component VAX-MOM intervention will be comprised of: training in communication, provider prompts, standing orders, and feedback on vaccination rates.
Study NCT04444518 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard vaccine education and processes provided to patients by obstetric practices.
Study NCT03880968 — intervention group
Intervention type: DRUG
Intervention: tapering or discontinuation of etanercept
Description: Active AS patients initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients who achieved inactive disease (ASDAS\<1.3, group A) at week 12 were either assigned to sequential tapering group (A1) or discontinuation group (A2), and those who reached low disease activity (LDA) (1.3≤ASDAS\<2.1, group B) were designated to sequential tapering group (B1), delayed tapering group (B2) or discontinuation group (B3).
Study NCT02694354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 685509
Study NCT02694354 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02960165 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual interface group
Description: First practice on virtual interface in order to evaluate the improvement and its influence on real interface performance (second practice).
Study NCT02960165 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Real interface group
Description: First practice on real interface in order to evaluate the improvement and its influence on virtual interface performance (second practice).
Study NCT06206577 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Horizontal ridge augmentation by symphyseal bone block placed and fixed buccally as onlay graft
Description: autogenous bone block harvested from chin area using piezosurgery and fixed buccally in deficient area with fixation screws
Study NCT06206577 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Horizontal ridge augmentation by symphyseal bone block interpositioned in space created between buccal and lingual cortex as inlay graft
Description: autogenous bone block harvested from chin area using piezosurgery and fixed in bone split created at deficient area with fixation screws
Study NCT02949193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: evogliptin
Description: evogliptin 5mg tablet qd + placebo tablet matching to sitagliptin 100mg
Study NCT02949193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: sitagliptin 100 mg tablet qd + placebo tablet matching to evogliptin 5mg
Study NCT00068393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin: 50 mg/m² IV slow push followed by gemcitabine 1500 mg/m² IV infusion over 30 minutes on day 1. Cycles repeat every 2 weeks.
Study NCT00068393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Doxorubicin: 50 mg/m² IV slow push followed by gemcitabine 1500 mg/m² IV infusion over 30 minutes on day 1. Cycles repeat every 2 weeks.
Study NCT00068393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF (granulocyte-colony stimulating factor)
Description: Patients will receive G-CSF at a subcutaneous dose of 5mcg/kg/day on days 2 or 3 to 10 or neulasta at a dose of 6mg on day 2. Growth factor must be administered as close as possible to 24 hours after the completion of chemotherapy. It is recommended that neulasta be administered only on day 2 due to its prolonged half-life.
Study NCT00068393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neulasta
Description: Patients will receive G-CSF at a subcutaneous dose of 5mcg/kg/day on days 2 or 3 to 10 or neulasta at a dose of 6mg on day 2. Growth factor must be administered as close as possible to 24 hours after the completion of chemotherapy. It is recommended that neulasta be administered only on day 2 due to its prolonged half-life.
Study NCT02320058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study NCT02320058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT02878564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Praziquantel
Description: 40 mg/kg, PO (orally administered tablets)
Study NCT05730959 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Sacral nerve modulation
Description: Implant of nerve stimulator
Study NCT01910545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTS167IV
Study NCT03866083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extracorporeal Cytokine hemadsorption therapy
Description: Hemoperfusion will be carried out for one session within 12 hours for all randomized patient using the adsorption columns for Jianfan Biotechnology Co., Zhuhai, China). The hemoperfusion apparatus will be connected in front of the hemodialyzer in series.
Study NCT03866083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment
Study NCT03866083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment
Study NCT03830684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baicalein Tablets 400mg
Description: 4 Baicalein Tablets and 2 placebo per time, three times a day
Study NCT03830684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baicalein Tablets 600mg
Description: 6 Baicalein Tablets per time, three times a day
Study NCT03830684 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: blank control 0mg
Description: 6 placebo per time, three times a day
Study NCT04724343 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin acetate
Description: 0.05-0.1 mg subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the cycle until the day of ovulation triggering.
Study NCT04724343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrorelix
Description: 0.25 mg subcutaneously (SC) once daily starting from the day detecting a leading follicle diameter ≥ 14 mm until the day of ovulation triggering.
Study NCT04724343 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin
Description: Dosage adjustment according to the ovarian response.
Study NCT04724343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin
Description: Dosage adjustment according to the ovarian response.
Study NCT04724343 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Chorionic Gonadotropin (hCG)
Description: Ovulation will be triggered by the administration of 10,000 IU of Human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm.
Study NCT04724343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Chorionic Gonadotropin (hCG)
Description: Ovulation will be triggered by the administration of 10,000 IU of Human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm.
Study NCT04293029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302
Description: SHR0302
Study NCT04106895 — intervention group
Intervention type: DRUG
Intervention: Fibryga
Description: Fibryga
Study NCT02538887 — intervention group
Intervention type: DEVICE
Intervention: Radio Frequency Surgical Detection
Study NCT03099213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAMIPRIL HOE498
Description: Pharmaceutical form:Tablet Route of administration: Oral
Study NCT03335007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclofenac
Description: Aceclofenac 100 mg tablet given one hour before starting the root canal treatment
Study NCT03335007 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet given one hour before starting the root canal treatment
Study NCT03995589 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking
Description: Technology-guided semi-supervised walking therapy
Study NCT03995589 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Go Home and Walk advice
Study NCT02357095 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: monitoring
Description: uterine artery chemo-embolization combined with suction curettage under different monitoring methods,such as hysteroscopic monitoring,ultrasonography monitoring and no monitoring
Study NCT03341143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant with Pembrolizumab
Description: FMT is a procedure in which fecal matter or stool is collected from a tested donor, mixed with a saline or other solution, strained and infused into the colon by doing a colonoscopy. The FMT consists of introducing normal bacterial flora contained in stool collected from a donor into your small intestine. In this case, the donor is patient with advanced melanoma who has been treated with a PD-1 inhibitor (nivolumab or pembrolizumab) and has been rendered disease-free as a result. The FMT will be performed on Cycle 1 Day 1.~Pembrolizumab, 200mg, through an IV over 30 minutes on Cycle 1 Day 1 (same day as the FMT, and then again on Day 1 of each 21-day cycle for an additional 3 cycles (Cycles 2 - 4).
Study NCT00078975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study NCT00078975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triapine
Study NCT02383368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP4132
Description: oral
Study NCT03526536 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: IV Novolin R human insulin
Description: Novolin R human insulin, Novo Nordisk Inc. Plainsboro, NJ
Study NCT02779699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL2846
Description: AL2846 p.o. qd
Study NCT01862263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: Orally active and highly selective inhibitor of DPP-4
Study NCT01862263 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin
Description: Long- acting human insulin analog indicated to improve glycemic control
Study NCT01862263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Long- acting human insulin analog indicated to improve glycemic control
Study NCT01862263 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo of vildagliptin
Study NCT01571999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled GSK573719
Description: All subjects will receive a single dose of GSK573719 (125mcg) in treatment period 1
Study NCT01571999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled GSK573719/vilanterol
Description: All subjects will receive a single dose of GSK573719 (125mcg)/vilanterol (25mcg) in treatment period 2
Study NCT04473378 — intervention group
Intervention type: DEVICE
Intervention: FreeStyle Libre Pro
Description: The device uses patches that attach to the skin on the back of the arm to measure blood sugar changes for the duration of the chemotherapy course.
Study NCT03743649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol
Description: Given IV
Study NCT03743649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam
Description: Given IV
Study NCT03743649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given IV
Study NCT03805984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INO-4500
Description: INO-4500 will be administered ID on Day 0 and Week 4.
Study NCT03743649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03805984 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered ID on Day 0 and Week 4.
Study NCT03805984 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CELLECTRA® 2000
Description: EP using the CELLECTRA® 2000 device will be administered following ID drug administration.
Study NCT03805984 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CELLECTRA® 2000
Description: EP using the CELLECTRA® 2000 device will be administered following ID drug administration.
Study NCT02135107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Rabeprazole 10 mg was administered orally twice daily during the treatment period for 8 weeks (unblinded).
Study NCT02135107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Rabeprazole 20 mg was administered orally twice daily during the treatment period for 8 weeks (unblinded).
Study NCT02135107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Rabeprazole 10 mg or 20 mg were administered orally twice daily during the treatment period (unblinded), and 10 mg was administered once daily during the maintenance period (double-blind).
Study NCT02135107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Rabeprazole 10 or 20 mg were administered orally twice daily during the treatment period (unblinded), and 10 mg was administered twice daily during the maintenance period (double-blind).
Study NCT01172496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treprostinil diethanolamine
Description: Subjects will be administered a 1 mg dose of treprostinil diethanolamine as a single tablet, and treprostinil diethanolamine oral solution 0.25 mg dose every 2 hours for four doses (1 mg total).
Study NCT02980419 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: presentation of visual and vestibular stimuli
Description: In each participant the investigators will assess verticality perception in whole-body upright position by use of the SVV, the SPV and the SHV after static roll-tilt at ±90deg over 5min. Measurements will be obtained on a motor-driven turntable and two different roll-tilt positions will be applied (±90°). A visual line (SVV), a rod (SHV) or the turntable itself will be adjusted to indicate perceived direction of vertical. A total of three measuring sessions, each lasting about 60 minutes are scheduled.
Study NCT03764826 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAABT
Description: The sound generators with CAABT will be used 15 min each session, three times a day
Study NCT03764826 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMT
Description: The sound generators with TMT will be used 15 min each session, three times a day
Study NCT02094976 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jackson surgical table
Description: After standard total intravenous anesthesia using propofol and remifentanil continous infusion, patients were turned to the prone position on a Jackson table with two padded supports on each side. The supports were positioned under the lateral chest and at the iliac crest.
Study NCT02094976 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wilson frame
Description: After standard total intravenous anesthesia using propofol and remifentanil continous infusion, patients were turned to the prone position on a Wilson frame. The supports were positioned vertically from shoulder to iliac crest.
Study NCT02094976 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Chest roll
Description: After standard total intravenous anesthesia using propofol and remifentanil continous infusion, patients were turned to the prone position on a chest roll. The supports were positioned vertically from shoulder to iliac crest.